(NASDAQ: HRTX) Heron Therapeutics's forecast annual revenue growth rate of 9.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Heron Therapeutics's revenue in 2025 is $155,097,000.On average, 6 Wall Street analysts forecast HRTX's revenue for 2025 to be $28,831,922,959, with the lowest HRTX revenue forecast at $27,636,399,316, and the highest HRTX revenue forecast at $29,842,250,456. On average, 6 Wall Street analysts forecast HRTX's revenue for 2026 to be $32,169,120,860, with the lowest HRTX revenue forecast at $30,548,196,165, and the highest HRTX revenue forecast at $33,500,332,769.
In 2027, HRTX is forecast to generate $37,512,304,751 in revenue, with the lowest revenue forecast at $33,801,047,305 and the highest revenue forecast at $43,262,553,441.